For more information, visit COMPANY PROFILES The company’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. Harpoon has also developed a proprietary ProTriTAC platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor.
Harpoon therapeutics trial#
HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. HPN328 targets DL元 and is in a Phase 1/2 trial for small cell lung cancer and other DL元-associated tumors. Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer. A high-level overview of Harpoon Therapeutics, Inc.
HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. Using its proprietary Tri-specific T cell Activating Construct (TriTAC) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The primary outcome measure will be safety and tolerability, and to determine a dose for Phase 2. HPN328 is being administered in fixed and step dosing to patients once weekly by intravenous infusion with dose escalation until a therapeutic dose level has been achieved. The Phase 1/2 trial is an open-label study of HPN328 to assess the safety, tolerability and pharmacokinetics in patients with advanced cancers associated with expression of DL元. HPN328 is a DL元 targeting TriTAC being studied as a single agent in an ongoing clinical trial for patients with small cell lung cancer, neuroendocrine and other DL元-associated tumors. Under this agreement, Harpoon is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab. “We are pleased with the compelling profile emerging in our monotherapy study and we plan to initiate combination trials in multiple lines of therapy for patients with small cell lung cancer, a disease with unmet medical need.” “We are pleased to enter into this clinical supply agreement with Roche as it enables us to investigate the impact of HPN328 on solid tumors in combination with atezolizumab and provide further insight into the capabilities of our TriTAC technology platform,” stated Julie Eastland, President and CEO, Harpoon Therapeutics.
Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq) for use in the company’s HPN328, a DL元 targeting TriTAC, clinical development program. recently announced it has entered into a clinical supply agreement with F.
0 kommentar(er)
